scispace - formally typeset
Open AccessJournal ArticleDOI

Myeloma: A malignant disorder of bone and soft tissue

Reads0
Chats0
TLDR
Despite many efforts over the years and the large number of treatment agents introduced, it is apparent that the authors do not have sufficient ability or knowledge to control this very troublesome disorder.
Abstract
The purpose of this brief report is to review a large series of cases of myeloma, a highly malignant tumor.  The disease was first described over 150 years ago, but not named myeloma until 1873. The lesion appears to be caused by the production of plasma cells in the bone marrow occasionally associated with amyloid. Patients present with pain in bones, principally spine, pelvis, ribs, calvarium and long bones. The sedimentation rate is elevated and marrow shows 10% plasma cells and the sedimentation rate is always elevated.  There is no identified genetic cause and the disease is not familial. The disease has a highly malignant potential. We treated 181 mature adult patients with tumor in multiple sites. 63% were dead of disease at an average of  4.5 years after diagnosis. The use of some new drugs have been helpful, chiefly lalanlidomide or bortezomib. Radiation appears to be useful for some lesions and bisphosphonates sometimes help support the bone structure. Despite many efforts over the years and the large number of treatment agents introduced, it is apparent that we do not have sufficient ability or knowledge to control this very troublesome disorder.

read more

Content maybe subject to copyright    Report

References
More filters
Journal Article

Risk factors for acute myeloid leukemia and multiple myeloma: a combination of GIS and case-control studies.

TL;DR: Occupational and lifestyle risk factors for AML and MM that were not apparent from census-tract-level data are identified and the significance of the risk factors in the study population is determined.
Journal Article

Recent advances in the management of multiple myeloma.

TL;DR: Simplified criteria for staging, uniform response criteria, more sensitive methods for detection of residual disease (immunofixation and free light chain assay), and recognition of potential adverse cytogenetic and genomic abnormalities have further refined the management of patients with myeloma.
Journal ArticleDOI

BaselinTc99-MIBI scanning predicts survival in multiple myeloma and helps to differentiate this disease from monoclonal gammopathy of unknown significance.

TL;DR: Two groups of MM patients whose actuarial survival correlated with low or high MIBI scores are identified, and these patients are identified as monoclonal gammopathy of unknown significance and MGUS patients.
Journal ArticleDOI

Atypical manifestations of multiple myeloma: Radiological appearance

TL;DR: This paper presents eight patients with atypical forms of multiple myeloma, which are found in about 5% of newly diagnosed patients with multipleMyelomas.